XML 69 R7.htm IDEA: XBRL DOCUMENT v2.4.0.8
CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)
In Thousands, unless otherwise specified
 9 Months Ended 12 Months Ended
Sep. 30, 2012
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2011
Cash flows from operating activities:        
Net loss   $ (76,678) $ (34,969) $ (11,485)
Adjustment to reconcile net loss to net cash used in operating activities:        
Depreciation and amortization expense   452 49 163
Loss on disposal of equipment   0 0 7
Gain on sale of marketable securities   (3,911) 0 0
Deferred taxes   1,052 (1,052)   
Non-cash stock-based compensation   2,530 1,394 3,001
Fair value of common stock warrants issued in exchange for services      0 108
Fair value of common stock issued in exchange for services   211 364 73
Change in fair value of common stock warrants   44,001 10,775 (8,981)
Change in fair value of contingent consideration   926 2,370 (109)
Changes in operating assets and liabilities:        
Accounts receivable   (3,683) 0 0
Inventories   (386) 0 0
Prepaid expenses and other assets   (832) (396) (99)
Accounts payable   684 641 500
Accrued expenses and other current liabilities   6,726 (139) 2,154
Net cash used in operating activities   (28,908) (20,963) (14,668)
Cash flows from investing activities:        
Change in restricted cash   (99)    (101)
Cash paid for acquisition of Abstral rights   (15,143)      
Cash received in Apthera acquisition   0 0 168
Proceeds from sale of marketable securities   3,911 0 0
Cash paid for purchase of equipment and furnishings   (705)    (53)
Cash transferred with the RXi spin-off      (87)   
Net cash provided by (used in) investing activities   (12,036) (87) 14
Cash flows from financing activities:        
Net proceeds from issuance of common stock   37,539 36,378 18,615
Cash paid for repurchase of warrants      (266)   
Net proceeds from exercise of stock options   567 21   
Proceeds from exercise of warrants   7,815 5,708 150
Proceeds from common stock issued in connection with ESPP   163 93 15
Net proceeds from issuance of RXi convertible notes payable      500 500
Net proceeds from issuance of long-term debt   9,865 0 0
Repayments of capital lease obligations   (25) (10) (84)
Net cash provided by financing activities   55,924 42,424 19,196
Net increase in cash and cash equivalents   14,980 21,374 4,542
Cash and cash equivalents at the beginning of period 11,433 32,807 11,433 6,891
Cash and cash equivalents at end of period   47,787 32,807 11,433
Supplemental disclosure of cash flow information:        
Cash received during the periods for interest 1 19   2
Cash paid during the periods for interest 1 547   6
Supplemental disclosure of non-cash investing and financing activities:        
Fair value of warrants issued in connection with common stock recorded as cost of equity 7,286 8,238   12,709
Issuance of common stock in exchange of outstanding warrants 0 0   3,120
Net liabilities distributed in connection with the RXi spin-off 2,246 0 2,159 0
Reclassification of warrant liabilities upon exercise 10,843 14,249 (10,843)   
Issuance of common stock in settlement of contingent purchase price consideration 1,579 1,247 1,579   
Change in fair value of marketable securities before settlement 2,678 (2,678)     
Fair value of shares issued to acquire NeuVax 0 0   6,367
Fair value of contingent purchase price consideration in connection with NeuVax acquisition 0 0   6,460
Net assets acquired, excluding cash of $168   $ 0 $ 0 $ 12,827